[16] [17] Semaglutide (as Wegovy) is further indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with obesity (initial BMI 30 kg/m 2 ) or who are overweight (initial BMI 27 kg/m 2 ) and have at least one weight-related comorbidity such as dysglycemia (prediabetes or type 2 diabetes), hypertension, dyslipidemia, or cardiovascular disease
The American Journal of Managed Care .
Retatrutide, a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors, represents a newer addition to this class
Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for diabetes but also prescribed for weight loss off-label quite often
Does the needle size or injection site affect how I should store my medication
Ishibashi, Y., Nishino, Y., Matsui, T., Takeuchi, M